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White adipose tissue (WAT) morphology character-
ized by hypertrophy (i.e., fewer but larger adipocytes)
associates with increased adipose inflammation,
lipolysis, insulin resistance, and risk of diabetes.
However, the causal relationships and the mecha-
nisms controlling WAT morphology are unclear.
Herein, we identified EBF1 as an adipocyte-
expressed transcription factor with decreased
expression/activity in WAT hypertrophy. In human
adipocytes, the regulatory targets of EBF1 were
enriched for genes controlling lipolysis and adipo-
cyte morphology/differentiation, and in both humans
and murine models, reduced EBF1 levels associated
with increased lipolysis and adipose hypertrophy.
Although EBF1 did not affect adipose inflammation,
TNFa reduced EBF1 gene expression. High-fat diet
intervention in Ebf1+/ mice resulted in more pro-
nounced WAT hypertrophy and attenuated insulin
sensitivity compared with wild-type littermate con-
trols. We conclude that EBF1 is an important regu-
lator of adipose morphology and fat cell lipolysis
and may constitute a link between WAT inflamma-
tion, altered lipid metabolism, adipose hypertrophy,
and insulin resistance.
INTRODUCTION
Disturbances in white adipose tissue (WAT) function, including
increased local inflammation and fat cell lipolysis, are linked to
insulin resistance, dyslipidemia, and atherosclerosis (Rosen
and Spiegelman, 2014; Sun et al., 2011). Results in recent years
have also highlighted the clinical importance of adipose tissue
morphology regardless of body fat mass. Thus, in lean as well
as in obese subjects, a phenotype characterized by fewer but
larger fat cells (adipose hypertrophy) correlates closely withCWAT dysfunction and insulin resistance, while a phenotype char-
acterized bymany small adipocytes (adipose hyperplasia) is pro-
tective (Arner et al., 2010b, 2011; Hoffstedt et al., 2010). Further-
more, adipose hypertrophy confers an increased risk for the
development of type 2 diabetes (Lo¨nn et al., 2010; Weyer
et al., 2000).
Although human adipocyte turnover (i.e., adipocyte birth/death
rate) is significantly reduced in adipose hypertrophy (Arner et al.,
2010b), the mechanisms promoting differences in adipose
morphology are still largely unknown. In addition, while adipose
morphology covaries with in vitro and in vivo insulin resistance
as well as changes in WAT inflammation and lipolysis, the causal
relationship between these factors is not known. Using an unbi-
ased approach, we set out to identify transcription factors (TFs)
associated with altered adiposemorphology, dissect their mech-
anismof action, andevaluate their clinical relevance.This resulted
in the identification of early B cell factor 1 (EBF1), a TF previously
implicated in adipogenesis (Akerblad et al., 2002; Fretz et al.,
2010), which through combined studies in human and murine
models was shown to also be an important regulator of adipose
morphology, lipolysis, and the development of insulin resistance.RESULTS
Adipose Morphology Is Characterized by Distinct
Functional and Transcriptional Alterations
The relationship between adipose morphology and metabolic
functionwas investigated in obese and nonobesewomen (cohort
1, n = 322), who were further subdivided into either those having
hyperplastic or hypertrophic subcutaneous WAT. In both weight
groups, subjects were matched for age, percent body fat, and
body mass index (BMI) (Table S1 available online). Irrespective
ofmorphology,WATof obese comparedwith nonobese subjects
was characterized by increased basal (i.e., non-hormone-
stimulated) (Figures 1A and S1A) and attenuated isoprenaline-
induced lipolysis (Figure 1B), insulin resistance at the adipocyte
level (Figure 1C) and whole-body level (Table S1), as well as
elevatedWAT release of the cytokines/chemokines tumor necro-
sis factor alpha (TNFa) (Figure 1D), chemokine (C-C motif) ligand
2 (CCL2) (Figure 1E), and interleukin 6 (IL6) (Figure S1B). Adiposeell Metabolism 19, 981–992, June 3, 2014 ª2014 Elsevier Inc. 981
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Figure 1. Relationship between Adipose
Morphology, Metabolic Phenotype, and
Gene Expression
(A–F) Effects of adipose morphology on in vitro (A)
basal lipolysis, (B) isoprenaline-stimulated lipolysis
(expressed as the quotient over basal lipolysis), (C)
insulin-stimulated lipogenesis, (D) TNFa secretion,
(E) CCL2 secretion, and (F) overall gene expres-
sion (shown as a PCA). For (A)–(E), results are
shown as mean ±SEM and were evaluated using
ANOVA followed by Fisher’s PLSD post hoc test.
Statistically significant differences (p < 0.05) are
denoted as follows: a = different within the weight
group, b = different from both measures in the
other weight group, c = different both within the
weight group and with both measures in the other
weight group, and d = different from one of the
measures in the other weight group. In (F), groups
are separated with 95% confidence interval if the
circles are not overlapping each other. See also
Figure S1 and Tables S1 and S2.
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EBF1 Regulates Adipocyte Morphology and Lipolysismorphology had a marked and statistically significant impact on
several of these parameters, particularly in the nonobese sub-
jects, where hypertrophy was associated with a more pernicious
phenotype. Although cohort 1 consisted only of women, similar
findings were also observed in men (cohort 2, n = 176,
Table S1 and values not shown).
To determine if morphology-associated metabolic profiles
were linked to changes in the transcriptome, analyses of global
gene expression in WAT from a previously described subset of
cohort 1 (cohort 3, n = 56) (Arner et al., 2012) were performed.
A principal component analysis (PCA), based on overall gene
expression, separated the four groups of subjects into three
distinct clusters: obese (both with hyperplasia and hypertrophy),
nonobese hypertrophy, and nonobese hyperplasia (Figure 1F).
Further comparisons demonstrated that (1) 619 genes were
altered by morphology in nonobese subjects, and (2) this gene
set displayed a considerable overlap (88%)with genes perturbed
in obese individuals (Figure S1C; Table S2). Gene set enrichment
analysis (GSEA) revealed that genes increased in nonobese982 Cell Metabolism 19, 981–992, June 3, 2014 ª2014 Elsevier Inc.hypertrophy belonged to proinflamma-
tory pathways (Figure S1D, left panel),
while genes that were decreased were
primarily associated with carbohydrate/
lipid metabolism and fat cell morphology
(Figure S1D, right panel).
Adipocyte EBF1 Expression and
Activity Is Linked to Adipose
Morphology
In order to identify TFs potentially causing
the gene expression alterations observed
in Figure 1F, we performed aMotif Activity
Response Analysis (MARA), based on the
global transcriptomic data mentioned
above, and combined it with our previ-
ously published MARA results during
human adipocyte differentiation (Arneret al., 2012). This identified seven TFs fulfilling the following
criteria: (1) present in in-vitro-differentiated adipocytes and (2)
exhibiting binding site motif activity patterns similar to that
observed in the PCA (i.e., altered in obesity and in nonobese sub-
jects with hyperplasia versus hypertrophy) (Table S3). Two out of
the seven TFs (EBF1 and hepatic leukemia factor [HLF]) dis-
played alterations in both binding site activity (Figure 2A and
Table S3, respectively) and mRNA levels (Table S3) in nonobese
subjects with hyperplasia. However, only EBF1 could be
confirmed by qPCR (Figures 2B and S2A), and this was corrobo-
rated by increased protein levels in nonobese individuals (Figures
2C and 2D). Thus, EBF1 mRNA, protein, and activity levels were
selectively increased in the nonobese subjects with hyperplasia,
and as a result, further studies were concentrated on this TF.
Consistent with previously published data in murine WAT (Jime-
nez et al., 2007), EBF1 mRNA expression was enriched in the
adipocyte fraction of WAT compared with intact adipose tissue
or leucocytes and macrophages (Figures 2E and 2F). A detailed
analysis of EBF1 mRNA levels during human adipocyte
A B
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Figure 2. Characterization of EBF1 Activity,
mRNA, and Protein Levels in Human Subcu-
taneous Adipose Tissue
(A and B) (A) Activity and (B) mRNA expression in
WAT from nonobese and obese subjects with
adipose different morphologies.
(C–G) (C) Western blot and (D) quantification of
EBF1 protein levels in WAT from nonobese in-
dividuals with hyperplasia or hypertrophy. Relative
EBF1 mRNA expression in (E) paired samples of
isolated adipocytes (Adipo) and intactWAT (n= 43);
(F) isolated macrophages (Macro), leukocytes
(Leuko), and adipocytes (n = 10); as well as (G)
during adipocyte differentiation in vitro (n = 3).
(H) Correlation between adipocyte EBF1 mRNA
expression and fat cell volume. Results were
evaluated using (in [A], [B], and [F]) ANOVA followed
by Fisher’s PLSD post hoc test, (in [D] and [E])
Student’s t test, and (in [H]) linear regression anal-
ysis. Statistically significant differences (p < 0.05)
are denoted as follows: a = different in a two-group
comparison or within the weight group, b =
different from both other measures, and d =
different from one of the measures in the other
weight group. See also Figure S2 and Table S3.
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EBF1 Regulates Adipocyte Morphology and Lipolysisdifferentiation showed an increase 12 hr after induction of adipo-
genesis that plateaued at day 4 (Figure 2G). Furthermore, adipo-
cyte volume correlated negatively with EBF1 gene expression in
isolated adipocytes (Figure 2H) andmRNA/activity in intact tissue
(Figures S2B and S2C). There was also a significant association
between EBF1 mRNA levels/activity and the gene expression
of leptin (LEP) and the Wnt1-inducible signaling pathway protein
2 (WISP2) (Figure S2D), two previously established markers of
adipose hypertrophy (Gustafson et al., 2013; Jerna˚s et al.,
2006; Skurk et al., 2007). These results prompted us to function-
ally evaluate the role of EBF1 in WAT and whether the altered
activity/expression of this TF is a cause or a consequence of dif-
ferences in adipose morphology and/or metabolic function.
EBF1 Regulates Genes Important for Adipocyte Lipid
Metabolism and Differentiation
To map direct transcriptional regulatory targets of EBF1,
genome-wide EBF1 chromatin immunoprecipitation (ChIP)Cell Metabolism 19, 981–followed by DNA sequencing (ChIP-
sequencing) analysis was performed in
human adipocytes differentiated in vitro.
Using a stringent approach that inter-
sects two independent peak-calling
methods, 10,428 unique EBF1-binding
regions were identified (Table S4). A de
novo search for enriched sequence
motifs in these sites identified an EBF1-
like binding motif as the most significantly
enriched motif (Figure 3A), which was
present in 78% of the identified binding
regions. There was a clear enrichment of
EBF1-binding sites in proximity to the
transcriptional start site (TSS) of the near-
est genes (Figure 3B), a distributionpattern that is in line with previous findings in B cells (Treiber
et al., 2010) and more recently in 3T3-L1 cells (Griffin et al.,
2013). In total, 2,501 genes were identified as potential EBF1
target genes (Table S5) with the detected EBF1-binding region
close to the respective TSS (±10 kb). Pathway enrichment anal-
ysis revealed these genes to be primarily involved in lipid meta-
bolism and WAT morphology (Figure 3C; Table S6).
Because TF/DNA interactions do not necessarily imply tran-
scriptional regulation, we performed global gene expression
profiling in human adipocytes transfected with siRNA targeting
EBF1 (knockdown efficiency shown in Figure S3A). A subset of
the identified potential EBF1 target genes was also regulated
by EBF1 RNAi treatment (Figure 3D; Table S5). A GSEA of the
upregulated genes displayed only three significantly enriched
gene sets, none of which were related to adipocyte metabolism
(Table S7). In contrast, among the downregulated genes, there
was a significant enrichment of several gene sets implicated in
WAT morphology and adipocyte metabolism (in particular lipid992, June 3, 2014 ª2014 Elsevier Inc. 983
Figure 3. Identification of Genes and Pathways Regulated by EBF1
(A) Cis-regulatory sequence motif identified in EBF1-bound sequences identified by ChIP-seq data.
(B) Histogram displaying the distance of EBF1-binding regions to the transcription start site.
(C) Identification of pathways enriched among genes bound by EBF1. Orange and purple bars depict mouse phenotype and gene ontology databases,
respectively.
(D) Genes bound by EBF1 and/or altered by EBF1 knockdown. According to ChIP-seq data, 2,501 genes bound EBF1; however, only 1,989 of these passed the
nonspecific filter for microarray analysis and were included in this Venn diagram. Details about the filters are in the Experimental Procedures.
(E) Identification of genes bound by EBF1, altered by EBF1 knockdown, and present in several of the enriched pathways. Genes bound and regulated by EBF1 as
well as altered by morphology are indicated by red arrows. See also Figure S3 and Tables S4, S5, S6, S7, and S8.
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Figure 4. Functional Evaluation of EBF1 Knockdown in Human Adipocytes
(A) Basal lipolysis determined in human adipocytes transfected with EBF1, PLIN1, EBF1/PLIN1, or control (nonsilencing) siRNAs.
(B) Effects of EBF1 gene knockdown on isoprenaline-stimulated lipolysis (expressed as the quotient over basal lipolysis).
(C) mRNA expression of the indicated genes following transfection of RNAi oligonucleotides targeting the same genes as in (A).
(D) Representative immunofluorescence images of adipocytes transfected as in (A). Cells were incubated with antibodies directed against PLIN1 (left column) and
LIPE (middle column), and the obtained images were merged (right column, with PLIN1 in red and LIPE in green).
(E) The quotient between LIPE and PLIN1 levels at the lipid droplet surface was determined for each transfection condition. For (A)–(C), results are based on
experiments performed in at least triplicate wells using cells obtained from aminimum of two different donors. Results in (D) and (E) were obtained as described in
Experimental Procedures. Data are shown as mean ±SEM and were evaluated using (in [A], [C], and [D]) ANOVA followed by Fishers PLSD post hoc test or (in [B])
Student’s t test. Statistically significant differences (p < 0.05) are denoted as follows: a = different from control and b = different from both control and siEBF1. See
also Figure S4.
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EBF1 Regulates Adipocyte Morphology and Lipolysismetabolism) (Table S7); 24 genes were considered as key EBF1
target genesbecause theywere included inmanyof the identified
pathways (Figure 3E). Several of these genesarewell-established
regulators of adipogenesis (e.g., peroxisome proliferator-
activated receptor gamma, PPARG, and nuclear receptor
corepressor 2, NCOR2) and lipolysis (e.g., hormone-sensitive
lipase [LIPE], patatin-like phospholipase domain containing 2
[PNPLA2], perilipin 1 [PLIN1], and cell-death-inducing DFFA-
like effector c [CIDEC]) (Girousse and Langin, 2012; Nofsinger
et al., 2008). By overlapping results from our EBF1 ChIP-
sequencing (ChIP-seq) analysis with the global transcriptome
data of human WAT with different morphologies, we found that
out of the 24 key genes bound and regulated by EBF1 (Figure 3E),
seven (PPARG, LIPE, PNPLA2, PLIN1, CIDEC, diacylglycerol
O-acyltransferase 1 [DGAT1], and adiponectin [ADIPOQ]) were
also expressed at significantly lower levels in nonobese subjects
with adipose hypertrophy versus hyperplasia (Figure S3B;CTable S8). These genes were considered to be of particular inter-
est and are highlighted by red arrows in Figures 3E and S3B.
EBF1 Depletion Alters Adipocyte Lipolysis
As evident from our clinical characterization of cohort 1, adipose
hypertrophy is associated with altered basal, as well as stimu-
lated, lipolysis, increased proinflammatory cytokine/chemokine
secretion, and decreased insulin sensitivity both in vivo and
in vitro (i.e., at the fat cell level). Although the functional role
of EBF1 in controlling adipogenesis is well-established, the ef-
fects on other aspects of adipocyte function have not been char-
acterized. To this end, human in-vitro-differentiated adipocytes
were transfected with siRNA targeting EBF1. While no effects
were observedonglucose transport (basal and insulin stimulated;
Figure S4A) or secretion of TNFa, CCL2, IL6, and adiponectin
(Figure S4B), basal (increased) and isoprenaline-induced
(decreased) lipolysis were significantly altered (Figures 4Aell Metabolism 19, 981–992, June 3, 2014 ª2014 Elsevier Inc. 985
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A Figure 5. Diet and Genotype Effects on
Body Composition and Fat Cell Diameter
(A–F) WT and Ebf1+/ mice were fed chow (Cd) or
high-fat diet (Hfd) for up to 10 weeks. Effects on (A)
total body weight, (B) total fat mass, and adipocyte
diameters in (C) inguinal (iWAT), (D) gonadal
(gWAT), (E) retroperitoneal (rpWAT), and (F)
mesenteric (mWAT) adipose tissue were deter-
mined. Results are based on measurements in all
available mice (5–10 per group) and are shown as
mean ±SEM. For Cd at baseline, differences were
assessed using Student’s t test and statistically
significant differences (p < 0.05) are marked with
an ‘‘a.’’ To evaluate diet- and genotype-specific
effects, data were analyzed using ANOVA followed
by Fishers PLSD post hoc test. Statistically sig-
nificant differences (p < 0.05) between groups at 3,
7, and 10 weeks are denoted as follows: a =
different between diet within a genotype, b =
different from both measures in the other geno-
type, c = different both between diet within the
genotype and with both measures in the other
genotype, and d = different from one of the mea-
sures in the other genotype. See also Figure S5.
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EBF1 Regulates Adipocyte Morphology and Lipolysisand 4B). Quantitative PCR and western blot confirmed the EBF1
RNAi microarray data (i.e., a significant 30%–40% downregula-
tion in the mRNA and protein expression of key lipolytic genes,
including PLIN1 and LIPE) (Figures 4C and S4C). A combined
decrease in the expression of PLIN1 and LIPE can result in
increased lipolysis in human adipocytes provided that the ratio
between LIPE and PLIN1 is increased at the lipid droplet surface
(Stenson et al., 2011). In order to dissect mechanisms by which
EBF1 controls basal lipolysis, human adipocytes were trans-
fected with siRNAs targeting EBF1, PLIN1, or both (Figure 4C).
While EBF1 and PLIN1 RNAi induced similar, albeit quantitatively
slightly different, increases in glycerol release (Figure 4A) and the
ratio of LIPE/PLIN1 protein at the lipid droplet surface (Figures 4D
and 4E), there was no additive effect of combining the two treat-
ments. The in vivo relevance of these findings was corroborated
by the significant negative association between EBF1 mRNA
levels in WAT and in vivo lipolysis (cohort 3, Figure S4D).986 Cell Metabolism 19, 981–992, June 3, 2014 ª2014 Elsevier Inc.EBF1 Reduction Promotes Adipose
Hypertrophy in Mice
In order to determine whether murine
Ebf1 expression was regulated by alter-
ations in fat mass in a similar manner as
observed in humans, publically available
transcriptional data of murine WAT de-
pots were retrieved. The results from
this analysis demonstrated that Ebf1
mRNA expression was significantly
reduced upon high-fat diet (Hfd) (p =
0.0034 for overall difference in five indi-
vidual studies; Table S9). To directly
determine the role of EBF1 in the devel-
opment of adipose morphology, we
used a murine knockout model. Because
Ebf1/ mice are lipodystrophic (Festa
et al., 2011; Fretz et al., 2010) and there-fore not suitable for studies of WAT function, Ebf1+/ animals
were generated and subjected to Hfd for up to 10 weeks. Recent
results have highlighted qualitative differences in the expand-
ability between gonadal (gWAT) and inguinal (iWAT) depots
(Wang et al., 2013). Assessments were therefore performed in
four separate regions: iWAT, gWAT, retroperitoneal (rpWAT),
and mesenteric (mWAT). At baseline, compared to wild-type
(WT), Ebf1+/ mice displayed similar total body weight, total fat
mass, lean body mass, brown adipose tissue (BAT), as well as
iWAT, gWAT, rpWAT, and mWAT depot weights (Figures 5 and
S5). During and at the end of the Hfd, both genotypes had, to a
similar degree, increased their total body weight, total fat
mass, lean body mass, BAT, and all but one WAT depot (the
exception being gWAT, which was slightly less increased in the
Ebf1+/ mice at week 10) (Figures 5 and S5). Analyses of fat
cell diameter demonstrated that, compared to WT littermates,
heterozygous animals on chow diet displayed consistently larger
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Figure 6. Diet and Genotype Effects on Lipolysis and Measures of Insulin Resistance
(A and B) (A) Lipolysis and (B) mRNA expression of indicated genes in inguinal adipose tissue (iWAT) from WT and Ebf1+/ mice.
(C–E) (C) Insulin and (D) glucose levels as well as (E) insulin tolerance tests (ITTs) at baseline and during Cd or Hfd at 3, 7, and 10 weeks in WT and Ebf1+/mice.
Results are based onmeasurements in all available mice (5–10 per group) and are shown as mean ±SEM. In two-group comparisons in (A)–(D) (i.e., for animals at
baseline) differences were assessed using Student’s t test and statistically significant differences (p < 0.05) are marked with an ‘‘a.’’ To evaluate diet- and ge-
notype-specific effects, data were analyzed using ANOVA followed by Fisher’s PLSD post hoc test. Statistically significant differences (p < 0.05) between groups
were observed at 10 weeks and are denoted as follows: a = different between diet within a genotype, c = different both between diet within the genotype and with
both measures in the other genotype, and d = different from one of the measures in the other genotype. In (E), note that there was no sign of glucose recovery at
the 150 min time point. As detailed in the Supplemental Experimental Procedures, this could depend on the fact that animals were fasted overnight prior to the
assessments.
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EBF1 Regulates Adipocyte Morphology and Lipolysisadipocytes in the studiedWAT depots over time (Figures 5C–5F).
While Hfd in general increased fat cell size, the differences
between genotypes persisted in all WAT depots up to 7 weeks
of hypercaloric intake. At 10 weeks of Hfd, the observed differ-
ences in adipocyte diameters were no longer evident in gWAT,
borderline significant in rpWAT (p = 0.061), and remained signif-
icant in iWAT and mWAT. Thus, while the fat cell diameter in
haploinsufficent mice fed Hfd plateaued at 115–120 mm after
3–7 weeks, WT littermates reached this size only at 10 weeks.
Effects of EBF1 Reduction on Lipolysis and Insulin
Sensitivity in Mice
To evaluate the metabolic phenotype of Ebf1 haploinsufficiency,
we determined lipolysis in intact iWAT, measured fasting plasma
insulin/glucose levels, and performed insulin tolerance tests
(ITTs). Compared to WT mice, lipolysis was higher in heterozy-
gous animals (Figure 6A), and this was accompanied by reduced
mRNA levels of Ebf1, Plin1, and Lipe (Figure 6B). Although Hfd
induced a significant increase in fasting insulin and a trend
toward higher glucose levels (Figures 6C and 6D), there were
no effects of genotype on these measures. However, when per-
forming ITTs, Ebf1+/mice at 10 (but not baseline), 3, or 7 weeks
of Hfd displayed a significantly attenuated response to insulinCbetween 30 and 150 min compared to pair-fed WT animals
(Figure 6E). This was independent of whether the comparisons
were made at each time point by calculating the area under
the curve (p = 0.028; data not shown) or expressing the results
as percent of baseline glucose values (data not shown). In
contrast, although WT animals on Hfd displayed slightly higher
glucose values at each time points in the ITT curves, they were
not statistically different from those of chow-fed mice. It should
be noted that the mice were generated on amixed genetic back-
ground (C57BL/6-129X1/SvJ) and fed Hfd for a relatively short
time period. These aspects may explain why WT littermates
did not develop pronounced insulin resistance at the end of the
diet intervention.
EBF1 Expression Is Regulated by TNFa
Because adiposemorphology andWAT inflammation are closely
associated, we hypothesized that proinflammatory adipokines
could affect EBF1 expression. This notion was corroborated by
the observation that EBF1 activity correlated negatively with
WAT secretion of TNFa, a cytokine with well-established effects
on adipocyte lipolysis, insulin sensitivity, and adipogenesis
(cohort 3, Figure 7A). This association was independent of BMI
(partial r = 0.47; p = 0.0001). Furthermore, in vitro experimentsell Metabolism 19, 981–992, June 3, 2014 ª2014 Elsevier Inc. 987
A B
Figure 7. Relationship between EBF1 and TNFa
(A) Linear regression analysis between WAT TNFa secretion in vitro and EBF1
activity. After correction for BMI, the correlation remained significant (see main
text).
(B) EBF1 mRNA expression following incubations with recombinant TNFa in
in-vitro-differentiated human adipocytes. Results are based on experiments
performed in duplicate wells using cells obtained from two different donors.
Data are shown as mean ±SEM and evaluated using Student’s t test. The
statistically significant difference (p < 0.05) is marked with an ‘‘a.’’
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gulated EBF1 expression (Figure 7B).
DISCUSSION
In vitro studies have conclusively demonstrated that EBF1 plays
a central role in adipogenesis, and the in vivo relevance of these
findings is evident from the fact that Ebf1/ mice are lipody-
strophic (Fretz et al., 2010). Our unbiased approach identified,
among a large number of TFs, adipocyte EBF1 expression and
activity to be closely linked to adipose morphology in human
WAT. The EBF1 regulatory cistrome included key genes involved
in lipid metabolism and adipocyte differentiation/morphology,
and EBF1 depletion led to altered lipolysis, increased insulin
resistance, and WAT hypertrophy. Although we cannot exclude
the possibility that reduced Ebf1 expression in other tissues
may contribute to the observed metabolic phenotype, these
data indicate that EBF1 is a central factor controlling the
morphologic and metabolic phenotype of WAT as well as
whole-body insulin sensitivity.
The gene set bound and regulated by EBF1 in primary human
adipocytes was determined and validated by combining tran-
scriptional profiling, ChIP-seq, and RNAi. Overall, this approach
identified genes involved in lipid metabolism and adipogenesis,
two processes that are essential for adipocyte function. In sup-
port of these observations, EBF1 RNAi resulted in increased
basal and attenuated stimulated lipolysis, most probably due
to reduced mRNA and protein levels of PLIN1 and LIPE, as
well as an altered ratio between these two proteins at the lipid
droplet surface. This is consistent with the lipolytic phenotype
observed in WAT hypertrophy and obesity. Current models posit
that the relative expression and the lipid-droplet-associated
interaction between coating proteins (e.g., PLIN1, CIDEA, and
CIDEC) and lipases (LIPE and PNPLA2) control the rate of basal
and stimulated lipolysis (reviewed in Girousse and Langin, 2012).
It is therefore conceivable that other factors, such as CIDEA and
PNPLA2, may also influence EBF1-mediated effects on lipolysis.
In contrast, the specific genes involved in determining adipose988 Cell Metabolism 19, 981–992, June 3, 2014 ª2014 Elsevier Inc.morphology are less evident. The observation that WAT hyper-
trophy is associated with reduced adipocyte turnover (Arner
et al., 2010b) suggests that genes involved in controlling adipo-
cyte birth/death rates may be of importance. Moreover, it has
been suggested that enlarged adipocyte size may represent a
state of impairedWAT expandability due to altered adipogenesis
(Tan and Vidal-Puig, 2008; Virtue and Vidal-Puig, 2010). Consis-
tent with this, EBF1, PPARG, and CEBPA mRNA levels in WAT
were lower in nonobese hypertrophy. As these three TFs
cross-talk by regulating the expression of each other, as well
as similar target genes (Griffin et al., 2013), it is tempting to spec-
ulate that EBF1 reduction, with concomitant alterations in
PPARg and CEBPa levels, results in WAT hypertrophy via
impaired fat cell differentiation. Because there are no established
in vitro techniques to evaluate direct effects on morphology, the
causal link between EBF1 downregulation andWAT hypertrophy
was studied in Ebf1+/ mice.
Compared with WT littermates, heterozygous animals dis-
played no significant changes in body composition or WAT/
BAT depot sizes. However, analogous with our findings in
humans, the expression of lipolytic regulators was decreased,
while spontaneous (basal) glycerol release was increased in
iWAT. Moreover, fat cell size was significantly larger in all four
studied WAT depots, but despite this, there was no difference
in insulin sensitivity when animals were fed chow diet. Because
both increased lipolysis and adipocyte size confer an increased
risk for metabolic complications, these findings prompted us to
explore the effects of a Hfd intervention. As expected, irrespec-
tive of genotype, 10 weeks of high-fat feeding induced a signifi-
cant increase in body weight, WAT depot sizes, and circulating
insulin concentrations. Heterozygous mice displayed signifi-
cantly larger fat cell size throughout the observation period, as
well as attenuated insulin sensitivity (determined by ITT) at the
end of the study. Notably, while our assessments in humans
were based on WAT from the abdominal subcutaneous region,
ourmurine data demonstrate that Ebf1 haploinsufficiency results
in similar alterations in adipose morphology in four different WAT
depots, including two visceral regions (gWAT andmWAT). Taken
together, these results suggest that reduced Ebf1 expression
results in WAT hypertrophy and increased basal lipolysis and
confers an increased risk of developing insulin resistance under
hypercaloric conditions. To what extent the secondary reduc-
tions in Pparg/Cebpa contribute to this phenotype is presently
unknown. It would therefore be of interest to study the effects
of thiazolidinediones in Ebf1+/ animals as well as to determine
the consequences of overexpressing Ebf1 in mice with geneti-
cally modified levels of Pparg/Cebpa.
Although the current clinical and transcriptomic analyses
confirm a tight association between adipose hypertrophy,
reduced insulin sensitivity, elevated basal lipolysis, and
increased local inflammation, the causal relationship between
these changes is not known. Even if our data suggest that
EBF1 affects adipose morphology and lipolysis, a combination
of ChIP-seq, transcriptional profiling, RNAi, and ELISA consis-
tently demonstrated that EBF1 reduction did not influence the
activity of inflammatory pathways in human adipocytes. In
contrast, TNFa downregulated adipocyte EBF1 expression,
and the levels of TNFa secretion correlated negatively with
EBF1 activity. Thus, adipose hypertrophy may not be a cause,
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via reduced EBF1 expression/activity. This hypothesis is sup-
ported by recent findings demonstrating that subcutaneous
WAT from lean and healthy young women display a high correla-
tion between adipose secretion of TNFa and adipose
morphology (Arner et al., 2010a).
Recent work explored the effects of Ebf1 depletion by adeno-
viral shRNA in the immortalized murine cell line 3T3-L1 (Griffin
et al., 2013). In analogy with our data, a significant but selective
decrease in adipogenic genes such as Pparg and Cebpa was
observed without a global reduction of fat-cell-enriched tran-
scripts. These results, together with the observation that EBF1
RNAi did not alter insulin sensitivity or adipokine secretion, sug-
gest that EBF1 knockdown does not induce significant dediffer-
entiating effects in vitro. However, in clear contrast to our present
data, Griffin and coworkers (Griffin et al., 2013) found a signifi-
cant enrichment in inflammatory signaling (although this was
probably regulated via indirect mechanisms), reduced glucose
transport, and attenuated TLR signaling (including reduced cyto-
kine release and LPS-stimulated lipolysis). These differences
imply that the cellular context in which EBF1 is studied impacts
strongly on the data, a notion which is supported and discussed
by Griffin et al. (2013) after comparing their ChIP-seq with similar
analyses performed in non-adipose cells.
Several groups have aimed to elucidate the mechanisms
underlying the development of adipose hypertrophy/hyperplasia
under isocaloric or hypercaloric conditions in different murine
WAT depots (reviewed in Berry et al., 2014). Using different tech-
niques to determine adipocyte formation, these studies have
come to somewhat divergent conclusions suggesting that
upon Hfd, hyperplasia primarily occurs in either iWAT (Joe
et al., 2009) or gWAT (Wang et al., 2013). In the latter work, the
authors also proposed that large adipocytes, at least under
some conditions, may in fact be new adipocytes formed through
adipogenesis. Our data, demonstrating similar phenotypes in
four different WAT depots of Ebf1+/, both before and after
Hfd, suggest that the effects of Ebf1 on adipocyte formation
are region independent and persist at the onset of diet-induced
obesity.
Our combined clinical and transcriptomic analyses identified
three distinct phenotypes—nonobese with hyperplasia, nonob-
esewith hypertrophy, and obese subjects—implying that nonob-
ese with WAT hypertrophy constitute a specific subgroup that,
although anthropometrically nonobese, displays a metabolic
profile that more closely resembles the obese state. In contrast,
obesity appears to override the effects of adipocyte size and
number, most probably due to several other associated distur-
bances. These observations, together with previous findings
demonstrating that WAT hypertrophy confers an increased risk
for future development of type 2 diabetes (Lo¨nn et al., 2010;
Weyer et al., 2000), suggest that lifestyle interventions should
be commenced early based on assessments of adipose
morphology already in the nonobese state.
Taken together, EBF1 is an important regulator of WAT
morphology and fat cell lipolysis by controlling distinct gene
sets and may therefore constitute a pathophysiological link
between adipose hypertrophy and common metabolic disor-
ders. Whether EBF1 is also a suitable therapeutic target remains
to be demonstrated.CEXPERIMENTAL PROCEDURES
Subjects
Cohorts 1–3, described in detail in Table S1 and Supplemental Experimental
Procedures, comprised healthy women and men subdivided into obese/
nonobese and hyperplastic/hypertrophic WAT. The study was approved by
the regional board of ethics, and written informed consent was obtained
from all participants.
Transcriptional Profiling and MARA
Gene expression profiling was performed using Affymetrix Human Gene 1.0
(cohort 3, previously presented in Arner et al., 2012) and Affymetrix Human
Gene 1.1 (EBF1 knockdown versus control) ST arrays (Affymetrix, Inc., Santa
Clara). Data were analyzed with packages available from Bioconductor (http://
www.bioconductor.org). Normalization and calculation of gene expression
was performed with the Robust Multichip Average expression measure using
oligo package (Carvalho and Irizarry, 2010). Prior to further analysis, a nonspe-
cific filter was applied to include genes with expression signal >30 in at least
20% of all samples. Limma package (Smyth, 2004) was used to identify the
differentially expressed genes that were ranked in the gene set enrichment
analyses, and PCA was performed using the FactomineR package. MARA
was performed exactly as described (Arner et al., 2012; Suzuki et al., 2009)
and detailed in Supplemental Experimental Procedures.
ChIP
Adipocytes differentiated in vitro were fixed in 1% formaldehyde for 15 min at
room temperature and quenched for 5 min by adding glycine to a final concen-
tration of 0.125 M. Cells were harvested, and nuclear fractions were enriched
by a brief sonication in lysis buffer A (10 mM Tris/Hcl [pH7.5], 10 mM NaCl,
3 mM MgCl2, 10mM KCl2, 0.05% Nonidet P-40, and 13 protease inhibitors
[Roche Complete EDTA-free cocktail tablets]) followed by centrifugation at
5000 3 g for 5 min. The collected pellets were suspended in 1,000 ml cell lysis
buffer B (50 mM Tris [pH 8.0], 1 mM EDTA, 0.5 mM EGTA, 1% Triton X-100,
0.1% Na-deoxycholate, 150 mM NaCl, and protease inhibitor). ChIP assays
were then performed following the protocol described in Gao et al., (2008).
Samples were immunoprecipitated with 5 mg custom-made EBF1 antibody
(Abmart, P.R. China) or rabbit IgG (Santa Cruz Biotechnology) at 4Covernight.
ChIP-Seq
ChIP-seq libraries were prepared using NEBnext ChIP-seq Library Prep Mas-
terMix Set (NewEnglandBiolabs, Ipswich) from 5 ng of anti-EBF1 and anti-IgG
ChIP DNA, respectively. Sequence data were generated with Illumina HiSeq
2000 single-read sequencing and aligned against the human genome (hg19,
NCBI) using Burrows-Wheeler Aligner (Li and Durbin, 2009) with default
parameters. The uniquely mapped reads were analyzed to identify EBF1-bind-
ing regions (with anti-IgG DNA as a control) by two different approaches—
MACS (Zhang et al., 2008) and Homer (Heinz et al., 2010)—using default
settings. Regions that were detected by both methods were considered as
EBF1-binding regions. An independent EBF1 ChIP-seq experiment demon-
strated a high reproducibility of the identified regions (Pearson correlation
r = 0.89) when comparing the normalized tag counts between replicates.
Gene Annotation Analysis
Genomic Regions Enrichment of Annotations Tool (GREAT) (McLean et al.,
2010) was employed to perform the enrichment analysis of gene annotation
in the proximity of EBF1-binding regions against the whole genome back-
ground. In the GREAT analysis, association of EBF1 genomic regions with
nearby genes was determined by the ‘‘basal plus extension’’ rule with the
parameter of 5 + 1 kb basal promoter and a more limited 10 kb extension.
Significantly enriched gene sets were selected by FDR q value < 0.05 for
both binomial and hypergeometric tests. Significantly enriched gene sets
between 15 and 600 genes were included.
GSEA
GSEA (Subramanian et al., 2005) was employed to analyze the altered gene
expression profiles following EBF1 knockdown in adipocytes and between
the human WAT with different morphologies. In order to identify core EBF1
target genes/pathways affected by altered EBF1 mRNA/protein levels inell Metabolism 19, 981–992, June 3, 2014 ª2014 Elsevier Inc. 989
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derived from the significantly enriched terms identified in the GREAT analysis
described above and contained only the genes associated with EBF1-binding
regions identified by ChIP-seq (Table S5).
Mice
Ebf1/mice were originally generated and supplied by Dr. Rudy Grosschedel
(Lin and Grosschedl, 1995). C57BL/6 and 129X1/SvJ mice were obtained from
the National Cancer Institute and The Jackson Laboratory (Bar Harbor),
respectively, and housed at Yale University School of Medicine. Ebf1+/ and
age-matched WT littermate control mice were generated and characterized
as described in the Supplemental Experimental Procedures. The Yale Medical
School Institutional Animal Care and Use Committee approved the purchase
and use of all animals.
Cell Culture
Cell culture experiments were performed on human WAT adipocytes and
mesenchymal stem cells differentiated in vitro. The isolation procedure and
culture/differentiation conditions have been described previously (Ehrlund
et al., 2013; van Harmelen et al., 2005). In-vitro-differentiated adipocytes
were stimulated with human recombinant TNFa (50 ng/ml, Sigma-Aldrich)
for 6 hr, upon which effects on EBF1 mRNA levels were measured.
RNAi
Human adipocytes differentiated in vitro were transfected with ON-
TARGETplus SMARTpool (Thermo Fisher Scientific, Lafayette) targeting
EBF1 (L-011848-01) or Non-targeting Control Pool (D-001810-10) siRNA and
HiPerfect Transfection Reagent (QIAGEN, Hilden) as described (Kulyte´ et al.,
2014). The cells were incubated for 48–72 hr, upon which functional assays
were performed and/or RNA/protein and culture media were collected.
RNA Isolation, cDNA Synthesis, and qPCR
Total RNAwas extracted using RNeasy Lipid TissueMini Kit/miRNeasymini kit
(QIAGEN, Hilden) or NucleoSpin RNA II kit (Macherey-Nagel, Du¨ren) according
to the manufacturers’ instructions. Subsequently, RNA concentration and
quality were measured using Nanodrop 2000 spectrophotometer (Thermo
Fisher Scientific, Lafayette) and Agilent 2100 Bioanalyzer (Agilent Technolo-
gies, Palo Alto), respectively. mRNA was reverse transcribed to cDNA using
Omniscript First-strand cDNA synthesis kit (QIAGEN) and random hexamer
primers (Invitrogen, Carlsbad). Assessment of mRNA expression was per-
formed as described (Pettersson et al., 2011)m and relative levels were calcu-
lated using a comparative Ct-method (i.e., 2DCt-target gene/2DCt-reference gene).
18S rRNA and LRP10 (human samples) as well as ACTB (murine samples)
were used to normalize the expression of all analyzed genes. TaqMan and
SYBR Green assays used in this study are listed in the Supplemental Experi-
mental Procedures.
Immunofluorescence and Imaging
All analyses were performed in human in-vitro-differentiated adipocytes as
described in detail in the Supplemental Experimental Procedures.
Fractionation of WAT
The stroma-vascular fraction of subcutaneous WAT from ten subjects was
washed in PBS/0.5% BSA/2 mM EDTA buffer and stained with anti-CD45
Pacific blue clone T29/33 (DakoCytomation, Glostrup) and anti-CD14 PE
(BD Biosciences, New Jersey) antibodies. After washing, cells were resus-
pended in PBS/0.1% BSA/2 mM/1 mM MgCl2/25 mM DNase buffer, passed
through a 70 mm cell mesh (BD Biosciences), and sorted using a FACSAria
III cell sorter (BD Biosciences). Leucocytes were defined as CD45+/CD14
while CD45+/CD14+ cells corresponded to the macrophage/monocyte
fraction. Cell purity was investigated after each sorting and constituted
95.1% ± 2.9% for the monocyte/macrophage and 98.8% ± 0.87% for the leu-
cocyte fraction.
Glycerol Release and Glucose Transport
The effects of EBF1 knockdown on basal/insulin-stimulated glucose uptake
and basal or isoprenaline-stimulated lipolysis in human adipocytes differenti-990 Cell Metabolism 19, 981–992, June 3, 2014 ª2014 Elsevier Inc.ated in vitro were determined as described previously (Dicker et al., 2009;
Mejhert et al., 2010).
Protein Secretion and Western Blot
Protein levels of human IL6, CCL2, TNFa (D6050, DCP00, and QTA00B; R&D
Systems, Minneapolis), and adiponectin (10-1193-01; Mercodia, Uppsala) in
conditioned media were measured using ELISA according to the manufac-
turer’s instructions. Western blot was performed as described previously
(Mejhert et al., 2013). Primary antibodies were PLIN1 (Progen, Heidelberg),
LIPE (Cell Signaling Technologies, Beverly), and b-actin (Sigma-Aldrich).
Statistical Analyses
Analyses were performed using standard software packages, and relevant
statistical methods are detailed in the figure legends and under the respective
subheadings in the Experimental Procedures. When performing ANOVA, post
hoc tests were only performed if the overall ANOVA p value was <0.05. To
facilitate the overview of statistical differences in multigroup comparisons, a
uniform lettering system was adopted and is explained in detail under each
figure legend. For data sets displaying nonnormal distribution, nonparametric
statistical tests or log-transformed values were used. Error bars in Figures 1
and 4–7 represent SEM.
Materials and Data
Transcriptional profiles are accessible using Gene Expression Omnibus (GEO)
accession numbers GSE25402 andGSE42680. For ChIP-seq results, both raw
and mapped data are available using GEO accession number GSE54889.
SUPPLEMENTAL INFORMATION
Supplemental Information includes five figures, nine tables, and Supplemental
Experimental Procedures and can be found with this article online at http://dx.
doi.org/10.1016/j.cmet.2014.03.032.
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